Strong recommendation is stated in the following scenarios: for starting SGLT2 inhibitors and weak recommendation for starting GLP-1 receptor agonists for patients with established CVD and CKD; and weak recommendation for starting SGLT2 inhibitors rather than GLP-1 receptor agonists for patients committed to further reducing their risk for CVD and CKD outcomes. The gene discussed is SLC5A2; the disease is chronic kidney disease.